-
As Roche eyes busy 2026, Vabysmo undershoots targets and Tecentriq fails early lung cancer study
29 Jan 2026 20:55 GMT
… ] more patients were put on Avastin and biosimilars.”
The branded intravitreal … early-stage non-small cell lung cancer.
The phase 3 IMpower030 trial …
-
Pharmac To Fund Five Medicines For Multiple Sclerosis, Breast Cancer, Eye Conditions, And Lung Cancer
12 Nov 2025 01:12 GMT
… , breast cancer, eye conditions, and lung cancer will benefit from five medicines … ROS1-positive non-small cell lung cancer.
Bevacizumab (Avastin) – secured ongoing access to … funding for faricimab (Vabysmo) and lung cancer treatments. It will use this …
-
<![CDATA[ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors]]>
13 Oct 2025 22:18 GMT
… trials exploring HER2 alterations in lung tumors, here are some of the … advanced squamous non–small cell lung cancer (NSCLC).
Previously, developers announced prespecified … “overcome the limitations of bevacizumab [Avastin] in treating squamous [NSCLC]” while …
-
Finishing Chemo with Stage 4 Lung Cancer: Facing Hope and Uncertainty
07 Aug 2025 01:09 GMT
… a stage 4 diagnosis of lung cancer.
After her diagnosis, she spent … (Keytruda [pembrolizumab]), two rounds of Avastin (bevacizumab), and one additional round …
-
Shorter pembrolizumab infusions ‘safe’ alternative for patients
05 Feb 2026 22:21 GMT
… , including melanoma, non-small cell lung cancer and triple-negative breast cancer … Oncology Center.
Most participants had lung cancer (43%) or melanoma (41%). Other … already been established for bevacizumab [Avastin, Genentech],” de Boer said.
“This …
-
Combining Avastin With Alecensa Shows Promise in Advanced ALK-Positive Lung Cancer
29 May 2025 23:14 GMT
… clinical trial found that adding Avastin (bevacizumab) to Alecensa (alectinib … lymphoma kinase (ALK)-positive lung cancer, which then delayed disease … 9% of non–small cell lung cancer (NSCLC) cases, the … (stage IV) non-squamous lung cancer, and about 17% had …
-
<![CDATA[FDA Oncology Update January 2026: New Horizons in Precision Medicine]]>
02 Feb 2026 20:18 GMT
… or metastatic non–small cell lung cancer (NSCLC) harboring activating HER2 (ERBB2 … treating an aggressive subset of lung cancer that has historically seen limited … who have previously received bevacizumab (Avastin) and mirvetuximab soravtansine-gynx (Elahere …
-
Biosimilar Mvasi Demonstrates Similar Ophthalmic Safety Profile to Reference Product Avastin
31 Jul 2025 19:25 GMT
… biosimilar of reference bevacizumab (Avastin; Genentech), demonstrated a … cancer, non–small cell lung cancer, glioblastoma, metastatic cervical … high similarity to Avastin without clinically meaningful … “Given that both Avastin and Mvasi require compounding …
-
Analysis of the Effects of Bevacizumab Combined with Chemoradiotherapy on VEGF, bFGF, and Let-7 Levels in Non-Small Cell Lung Cancer and the Factors Influencing Therapeutic Efficacy: A Retrospective Cohort Study
02 Dec 2024 18:59 GMT
… subtypes, non-small cell lung cancer (NSCLC) predominates, accounting … of lung cancer and induce cell cycle arrest of lung cancer … JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, … AB, et al. Bevacizumab (Avastin®) in cancer treatment: a …
-
Lung Cancer Therapeutics Market Analysis by treatment into Chemotherapy, Targeted Therapy, Radiotherapy and Biological Therapy Through 2034 | Future Market Insights, Inc.
27 Nov 2024 14:30 GMT
… lung cancer therapeutics market. Lung cancer, especially non-small cell lung cancer NSCLC … of Roche's Avastin, in the UK. … including metastatic colorectal and lung cancers, among others, as … small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). …
About
© 1995-2026